Integrated Filing — IndAS



General information about company
Scrip Code 500126
NSE Symbol PGHL
MSEI Symbol NOTLISTED
ISIN INE199A01012
Name of company PROCTER & GAMBLE HEALTH LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Jul-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 29-May-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 26-Mar-2025
Description of presentation currency INR (in Actuals)
Reporting Type Half Yearly
Reporting Quarter Yearly
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 29-May-2025   12:40:00
End date and time of board meeting 29-May-2025   17:14:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2022-08-22
Indicate Company website link for updated RPT policy of the Company www.pghlhealthindia.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
Not applicable n



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Jul-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 3109900000 9341700000
Other income 31100000 103500000
Total income 3141000000 9445200000
2 Expenses
(a) Cost of materials consumed 908200000 2005900000
(b) Purchases of stock-in-trade 137200000 471600000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade -58200000 147500000
(d) Employee benefit expense 487900000 1420600000
(e) Finance costs 1300000 4300000
(f) Depreciation, depletion and amortisation expense 53700000 166900000
(f) Other Expenses
1 Other Expenses 825600000 2112200000
Total other expenses 825600000 2112200000
Total expenses 2355700000 6329000000
3 Total profit before exceptional items and tax 785300000 3116200000
4 Exceptional items 0 0
5 Total profit before tax 785300000 3116200000
6 Tax expense
7 Current tax 207100000 777000000
8 Deferred tax -33600000 -4900000
9 Total tax expenses 173500000 772100000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 611800000 2344100000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 611800000 2344100000
17 Other comprehensive income net of taxes -8000000 -26200000
18 Total Comprehensive Income for the period 603800000 2317900000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 166000000 166000000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 5369600000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 36.86 141.22
Diluted earnings (loss) per share from continuing operations 36.86 141.22
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 36.86 141.22
Diluted earnings (loss) per share from continuing and discontinued operations 36.86 141.22
24 Debt equity ratio 0 0
25 Debt service coverage ratio 0 0
26 Interest service coverage ratio 0 0
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) 1.tThe above audited financial results for the quarter and nine months financial year ended March 31, 2025 have been reviewed by the Audit Committee and taken on record in the meeting of the Board of Directors held on May 29, 2025 . These financial results have been subjected to an audit by the statutory auditors of the Company, who have expressed an unmodified opinion thereon. These financial results are prepared and published in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. n2.tThis Statement has been prepared in accordance with the Companies Indian Accounting Standards Rules, 2015 prescribed under Section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. n3.tThe Company has identified Pharmaceuticals as its single primary reportable segment in accordance with the requirement of Ind AS 108 Operating Segments. Accordingly no separate segment information has been provided. n4.tThe Board of Directors of the Company, on January 23, 2025, approved the change of the Financial Year end from June 30th to March 31st. Accordingly, the current Financial Year of the Company viz., 2024-25 shall be for a period of nine months commencing on July 1, 2024, and ending on March 31, 2025. Due to this change of period, the figures of the current period are not comparable with those of the previous year. n5.tA. The figures for the quarter ended March 31, 2025 are the balancing figures between audited figures in respect of nine months financial year ended March 31, 2025 and the limited reviewed year to date figures up to six months period ended December 31, 2024 of the current nine months Financial Year . nB. For the purpose of comparibility, Figures for 9 month period ended 31 March 2024 have been presented in the audited financial results. n6.tThe audited financial results are available on the website of the Company (www.pghealthindia.com) and on the websites of BSE (www.bseindia.com) and NSE (www.nseindia.com). n7.tThe Board of Directors at its meeting held on May 29th 2025, have recommended pau,emt of final dividend of 45 per equity share (face value Rs.10) is payable subject to the approval of the shareholders at the annual general meeting. n n8.tDuring the quarter ended June 30, 2024, the Company had discontinued production of injections at its manufacturing plant in Goa effective September 30, 2023, as the Company had started to source injections portfolio of its products from a contract manufacturer. Post evaluation of various alternatives, during the quarter ended June 30, 2024, the Company had entered into an agreement for sale of the assets of its injection plant for a consideration of 790 Lakhs and impaired the balance amount of 627 Lakhs. Based on above, the company had re-evaluated the usability of assets in their capital work in progress and thereby impaired other related assets by an amount of 1392 Lakhs. The above total amount of 2 019 Lakhs was disclosed as an exceptional item for the quarter and the year ended June 30, 2024. n n9.tPrevious year's or period's figures have been regrouped or rearranged or reclassified wherever necessary to conform to current period's classification. n n10.tThe Company does not have a subsidiary, an associate or a joint venture as at 31st March, 2025. n n n



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Jul-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 1046300000
Capital work-in-progress 109600000
Investment property 43700000
Goodwill 0
Other intangible assets 71100000
Intangible assets under development 0
Biological assets other than bearer plants 0
Investments accounted for using equity method 0
Non-current financial assets
Non-current investments 0
Trade receivables, non-current 0
Loans, non-current 101700000
Other non-current financial assets 47900000
Total non-current financial assets 149600000
Deferred tax assets (net) 350600000
Other non-current assets 907200000
Total non-current assets 2678100000
2 Current assets
Inventories 1093700000
Current financial asset
Current investments 0
Trade receivables, current 1454000000
Cash and cash equivalents 1820800000
Bank balance other than cash and cash equivalents 64700000
Loans, current 15900000
Other current financial assets 175100000
Total current financial assets 3530500000
Current tax assets (net) 0
Other current assets 639700000
Total current assets 5263900000
3 Non-current assets classified as held for sale 0
4 Regulatory deferral account debit balances and related deferred tax Assets 0
Total assets 7942000000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 166000000
Other equity 5203600000
Total equity attributable to owners of parent 5369600000
Non controlling interest
Total equity 5369600000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises 0
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 0
Total Trade payable 0
Other non-current financial liabilities 48100000
Total non-current financial liabilities 48100000
Provisions, non-current 361200000
Deferred tax liabilities (net) 0
Deferred government grants, Non-current 0
Other non-current liabilities 10000000
Total non-current liabilities 419300000
Current liabilities
Current financial liabilities
Borrowings, current 0
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 120800000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1595200000
Total Trade payable 1716000000
Other current financial liabilities 194700000
Total current financial liabilities 1910700000
Other current liabilities 138200000
Provisions, current 69700000
Current tax liabilities (Net) 34500000
Deferred government grants, Current 0
Total current liabilities 2153100000
3 Liabilities directly associated with assets in disposal group classified as held for sale 0
4 Regulatory deferral account credit balances and related deferred tax liability 0
Total liabilities 2572400000
Total equity and liabilites 7942000000
Disclosure of notes on assets and liabilities Textual Information(1)



Text Block
Textual Information(1) Note from cashflow: nThe above Cash Flow Statement has been prepared under the “Indirect Method” as set out in the Indian Accounting Standard (Ind AS 7) - Statement of Cash Flows.



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Oct-2024 01-Jul-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Oct-2024 01-Jul-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Re-measurement gains/(losses) on defined benefit plans -10700000 -35000000
Total Amount of items that will not be reclassified to profit and loss -10700000 -35000000
2 Income tax relating to items that will not be reclassified to profit or loss -2700000 -8800000
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss
5 Total Other comprehensive income -8000000 -26200000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jul-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 3116200000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 4300000
Adjustments for decrease (increase) in inventories -2600000
Adjustments for decrease (increase) in trade receivables, current -597200000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -72400000
Adjustments for decrease (increase) in other non-current assets 0
Adjustments for other financial assets, non-current 15800000
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 69300000
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -104600000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 166900000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 0
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 70400000
Adjustments for share-based payments 8000000
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) -29700000
Other adjustments for non-cash items -3500000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -616100000
Net cash flows from (used in) operations 2500100000
Dividends received 0
Interest paid 0
Interest received 0
Income taxes paid (refund) 813200000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities 1686900000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 79400000
Purchase of property, plant and equipment 0
Proceeds from sales of investment property 0
Purchase of investment property 86000000
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 71500000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 31000000
Net cash flows from (used in) investing activities 95900000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 0
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 0
Repayments of borrowings 0
Payments of lease liabilities 23400000
Dividends paid 2324000000
Interest paid 0
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities -2347400000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -564600000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -564600000
Cash and cash equivalents cash flow statement at beginning of period 2387300000
Cash and cash equivalents cash flow statement at end of period 1822700000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 Haribhakti & Co LLP Yes 25-Jul-2025


Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 5367000 470000 2400000
2 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 6667000 1444000 3600000
3 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Affiiliate reimbursement receipt Approved 36503000 99390000 69500000
4 PROCTER & GAMBLE HEALTH LIMITED GILLETTE INDIA LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 1727000 336000 700000
5 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE INTERNATIONAL OPERATIONS- SA Dubai Group Company Any other transaction Affiiliate reimbursement receipt Approved 29000 0 0
6 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Affiiliate reimbursement receipt Approved 9474000 12077000 11472000
7 PROCTER & GAMBLE HEALTH LIMITED PT PROCTER & GAMBLE HOME PRODUCTS INDONESIA Group Company Any other transaction Affiiliate reimbursement receipt Approved 82000 28000 100000
8 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA SINGAPORE BRANCH Group Company Any other transaction Affiiliate reimbursement receipt Approved 381000 255000 400000
9 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Affiiliate reimbursement receipt Approved 1805000 0 0
10 PROCTER & GAMBLE HEALTH LIMITED P&G HEALTH AUSTRIA GMBH & CO. OG Group Company Sale of goods or services Approved 109578000 60711000 174600000
11 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Rent Approved 7372000 0 1800000
12 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE COMPANY Ultimate Parent Company Any other transaction Rendering of Contract R&D Approved 63327000 55641000 63300000
13 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Purchase of goods or services Approved 3244000 10084000 13328000
14 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 46200000 0 0
15 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 39109000 13095000 12700000
16 PROCTER & GAMBLE HEALTH LIMITED GILLETTE DIVERSIFIED OPERATIONS PVT LTD Group Company Any other transaction Affiliate Reimbursements payment Approved 4187000 1557000 1500000
17 PROCTER & GAMBLE HEALTH LIMITED GILLETTE INDIA LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 7248000 3529000 2600000
18 PROCTER & GAMBLE HEALTH LIMITED GILLETTE INDIA LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 103000 104000 100000
19 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE US BUSINESS SERVICES COMPANY Group Company Any other transaction Affiliate Reimbursements payment Approved 153000 401000 200000
20 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HYGIENE & HEALTH CARE LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 841000 932000 800000
21 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Affiliate Reimbursements payment Approved 702000 1020000 700000
22 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE DISTRIBUTING LLC Group Company Purchase of fixed assets Approved 13000 548000 500000
23 PROCTER & GAMBLE HEALTH LIMITED THE PROCTER & GAMBLE US BUSINESS SERVICES COMPANY Group Company Any other transaction Import of Services Approved 27933000 7738000 7800000
24 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE PHILIPPINES BUSINESS SERVICES- INC. Group Company Any other transaction Import of Services Approved 45354000 14971000 19200000
25 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA SWITZERLAND Group Company Purchase of goods or services Approved 6605000 0 11400000
26 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA SINGAPORE BRANCH Group Company Purchase of goods or services Approved 3197000 16626000 4900000
27 PROCTER & GAMBLE HEALTH LIMITED Procter & Gamble Overseas India BV, The Netherlands Parent Company Dividend paid Approved 688085000 0 0
28 PROCTER & GAMBLE HEALTH LIMITED PROCTER & GAMBLE HOME PRODUCTS PRIVATE LIMITED Group Company Any other transaction Rent Approved 11636000 3162000 3100000
Total value of transaction during the reporting period 1126922000